Shandong Xinhua Pharmaceutical Co Ltd Net Assets

Latest as of June 2025: CN¥5.36 Billion CNY ≈ $785.07 Million USD

Shandong Xinhua Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) has net assets worth CN¥5.36 Billion CNY (≈ $785.07 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.24 Billion ≈ $1.35 Billion USD) and total liabilities (CN¥3.87 Billion ≈ $566.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Shandong Xinhua Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥5.36 Billion
% of Total Assets	58.08%
Annual Growth Rate	11.34%
5-Year Change	53.85%
10-Year Change	N/A
Growth Volatility	5.77

Net Assets of Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)

Net assets of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See how leveraged is Shandong Xinhua Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Annual Net Assets for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)

The table below shows the annual net assets of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. For live market cap and overall valuation, see 000756 stock market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥5.22 Billion ≈ $763.48 Million	+9.25%
2023-12-31	CN¥4.78 Billion ≈ $698.84 Million	+9.79%
2022-12-31	CN¥4.35 Billion ≈ $636.53 Million	+19.14%
2021-12-31	CN¥3.65 Billion ≈ $534.28 Million	+7.66%
2020-12-31	CN¥3.39 Billion ≈ $496.25 Million	+9.03%
2019-12-31	CN¥3.11 Billion ≈ $455.17 Million	+11.23%
2018-12-31	CN¥2.80 Billion ≈ $409.22 Million	+8.42%
2017-12-31	CN¥2.58 Billion ≈ $377.46 Million	+24.05%
2016-12-31	CN¥2.08 Billion ≈ $304.27 Million	+4.80%
2015-12-31	CN¥1.98 Billion ≈ $290.33 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shandong Xinhua Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 233.2% over the analyzed period, indicating profitable operations and earnings retention.

Shandong Xinhua Pharmaceutical Co Ltd Net Assets Breakdown (December 2024)

Shandong Xinhua Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2024.

Component	Amount	Percentage
Retained Earnings	CN¥2.55 Billion	51.09%
Other Components	CN¥2.44 Billion	48.91%
Total Equity	CN¥4.99 Billion	100.00%

Shandong Xinhua Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Shandong Xinhua Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Daou Tech KO:023590	$903.60 Million
Apex Dynamics Inc. TW:4583	$904.25 Million
IRB-Brasil Resseguros S.A. SA:IRBR3	$905.01 Million
Eckert & Ziegler Strahlen- und Medizintechnik AG F:EUZ	$905.45 Million
ASA Gold and Precious Metals Ltd NYSE:ASA	$903.51 Million
Bata India Limited NSE:BATAINDIA	$903.21 Million
Energi Mega Persada Tbk JK:ENRG	$903.11 Million
Whirlpool China Co Ltd SHG:600983	$902.84 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shandong Xinhua Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 4,553,103,870 to 4,991,588,525, a change of 438,484,655 (9.6%).
Net income of 470,023,746 contributed positively to equity growth.
Dividend payments of 225,847,089 reduced retained earnings.
Other factors increased equity by 194,307,998.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥470.02 Million	+9.42%
Dividends Paid	CN¥225.85 Million	-4.52%
Other Changes	CN¥194.31 Million	+3.89%
Total Change	CN¥-	9.63%

Book Value vs Market Value Analysis

This analysis compares Shandong Xinhua Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.71x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 3.13x to 1.71x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CN¥3.99	CN¥12.48	x
2018-12-31	CN¥4.32	CN¥12.48	x
2019-12-31	CN¥4.77	CN¥12.48	x
2020-12-31	CN¥5.18	CN¥12.48	x
2021-12-31	CN¥5.53	CN¥12.48	x
2022-12-31	CN¥6.16	CN¥12.48	x
2023-12-31	CN¥6.75	CN¥12.48	x
2024-12-31	CN¥7.31	CN¥12.48	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shandong Xinhua Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.42%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 5.55%
• Asset Turnover: 0.94x
• Equity Multiplier: 1.81x
Recent ROE (9.42%) is above the historical average (8.89%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	4.41%	2.31%	0.80x	2.38x	CN¥-105.36 Million
2016	6.15%	3.05%	0.85x	2.38x	CN¥-76.57 Million
2017	8.45%	4.64%	0.86x	2.13x	CN¥-38.41 Million
2018	9.33%	4.82%	0.88x	2.20x	CN¥-17.89 Million
2019	10.10%	5.35%	0.87x	2.17x	CN¥3.06 Million
2020	10.08%	5.41%	0.85x	2.20x	CN¥2.48 Million
2021	10.05%	5.31%	0.89x	2.11x	CN¥1.75 Million
2022	9.96%	5.48%	0.91x	2.00x	CN¥-1.45 Million
2023	10.90%	6.13%	0.98x	1.82x	CN¥41.20 Million
2024	9.42%	5.55%	0.94x	1.81x	CN¥-29.14 Million

Industry Comparison

This section compares Shandong Xinhua Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,632,405,673
Average return on equity (ROE) among peers: 7.53%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shandong Xinhua Pharmaceutical Co Ltd (000756)	CN¥5.36 Billion	4.41%	0.72x	$903.57 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.97 Billion	4.04%	0.54x	$488.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$560.87 Million	4.60%	0.22x	$360.39 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.02 Billion	12.46%	0.13x	$4.73 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.04 Billion	4.29%	0.46x	$2.58 Billion
Wedge Industrial Co Ltd (000534)	$0.00	0.00%	0.00x	$1.20 Billion
Yunnan Baiyao Group Co Ltd (000538)	$18.14 Billion	17.33%	0.53x	$14.52 Billion
Hainan Haiyao Co Ltd (000566)	$491.82 Million	6.71%	1.19x	$755.58 Million
Tus Pharmaceutical Group Co Ltd (000590)	$280.91 Million	1.46%	1.58x	$272.98 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$5.57 Billion	7.36%	1.59x	$920.83 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$7.25 Billion	17.08%	0.09x	$3.02 Billion

About Shandong Xinhua Pharmaceutical Co Ltd

SHE:000756 China Drug Manufacturers - Specialty & Generic

Market Cap

$903.57 Million

CN¥6.17 Billion CNY

Market Cap Rank

#8983 Global

#2117 in China

Share Price

CN¥12.48

Change (1 day)

+0.00%

52-Week Range

CN¥11.95 - CN¥18.15

All Time High

CN¥44.80